Lab Study Shows that J&J’s COVID Shot Produces Zero Antibody Protection Against Omicron Variant
Posted on 12/16/2021
In the U.S., the three approved COVID vaccine shots are the two-doses of Pfizer, two-doses of Moderna, and the singular shot of Johnson & Johnson (J&J). COVID booster shots are also approved. As the omicron coronavirus variant spreads across the globe, global health officials are scrambling to study how to treat people. In the U.S, the CDC estimates know that the omicron COVID variant accounts for 3% of all new cases nationwide. Diving into to New York and New Jersey, this new variant makes up 13% of new cases, impacting vaccinated COVID persons.
Approximately 17 million Americans received the J&J shot, accounting for less than 10% of vaccinations in the U.S.
South African virologist Penny Moore who works at University of the Witwatersrand in Johannesburg, South Africa, discovered that a key measure of antibody levels dropped from 303 against the original COVID-19 strain to undetectable levels against omicron COVID in those with the J&J shot. The J&J study was conducted under test-tube conditions with human blood plasma. The study has not been published yet.
To make matters worse for the J&J COVID shots, the Centers for Disease Control and Prevention (CDC) advisers are looking into limits in the Johnson & Johnson vaccine because of continued blood clot issues. The blood clot issue for those shots were in higher numbers among women. U.S. officials temporarily halted use of the single dose J&J vaccine in April 2021.
